Tag Archives: organic
#435106 Could Artificial Photosynthesis Help ...
Plants are the planet’s lungs, but they’re struggling to keep up due to rising CO2 emissions and deforestation. Engineers are giving them a helping hand, though, by augmenting their capacity with new technology and creating artificial substitutes to help them clean up our atmosphere.
Imperial College London, one of the UK’s top engineering schools, recently announced that it was teaming up with startup Arborea to build the company’s first outdoor pilot of its BioSolar Leaf cultivation system at the university’s White City campus in West London.
Arborea is developing large solar panel-like structures that house microscopic plants and can be installed on buildings or open land. The plants absorb light and carbon dioxide as they photosynthesize, removing greenhouse gases from the air and producing organic material, which can be processed to extract valuable food additives like omega-3 fatty acids.
The idea of growing algae to produce useful materials isn’t new, but Arborea’s pitch seems to be flexibility and affordability. The more conventional approach is to grow algae in open ponds, which are less efficient and open to contamination, or in photo-bioreactors, which typically require CO2 to be piped in rather than getting it from the air and can be expensive to run.
There’s little detail on how the technology deals with issues like nutrient supply and harvesting or how efficient it is. The company claims it can remove carbon dioxide as fast as 100 trees using the surface area of just a single tree, but there’s no published research to back that up, and it’s hard to compare the surface area of flat panels to that of a complex object like a tree. If you flattened out every inch of a tree’s surface it would cover a surprisingly large area.
Nonetheless, the ability to install these panels directly on buildings could present a promising way to soak up the huge amount of CO2 produced in our cities by transport and industry. And Arborea isn’t the only one trying to give plants a helping hand.
For decades researchers have been working on ways to use light-activated catalysts to split water into oxygen and hydrogen fuel, and more recently there have been efforts to fuse this with additional processes to combine the hydrogen with carbon from CO2 to produce all kinds of useful products.
Most notably, in 2016 Harvard researchers showed that water-splitting catalysts could be augmented with bacteria that combines the resulting hydrogen with CO2 to create oxygen and biomass, fuel, or other useful products. The approach was more efficient than plants at turning CO2 to fuel and was built using cheap materials, but turning it into a commercially viable technology will take time.
Not everyone is looking to mimic or borrow from biology in their efforts to suck CO2 out of the atmosphere. There’s been a recent glut of investment in startups working on direct-air capture (DAC) technology, which had previously been written off for using too much power and space to be practical. The looming climate change crisis appears to be rewriting some of those assumptions, though.
Most approaches aim to use the concentrated CO2 to produce synthetic fuels or other useful products, creating a revenue stream that could help improve their commercial viability. But we look increasingly likely to surpass the safe greenhouse gas limits, so attention is instead turning to carbon-negative technologies.
That means capturing CO2 from the air and then putting it into long-term storage. One way could be to grow lots of biomass and then bury it, mimicking the process that created fossil fuels in the first place. Or DAC plants could pump the CO2 they produce into deep underground wells.
But the former would take up unreasonably large amounts of land to make a significant dent in emissions, while the latter would require huge amounts of already scant and expensive renewable power. According to a recent analysis, artificial photosynthesis could sidestep these issues because it’s up to five times more efficient than its natural counterpart and could be cheaper than DAC.
Whether the technology will develop quickly enough for it to be deployed at scale and in time to mitigate the worst effects of climate change remains to be seen. Emissions reductions certainly present a more sure-fire way to deal with the problem, but nonetheless, cyborg plants could soon be a common sight in our cities.
Image Credit: GiroScience / Shutterstock.com Continue reading
#431559 Drug Discovery AI to Scour a Universe of ...
On a dark night, away from city lights, the stars of the Milky Way can seem uncountable. Yet from any given location no more than 4,500 are visible to the naked eye. Meanwhile, our galaxy has 100–400 billion stars, and there are even more galaxies in the universe.
The numbers of the night sky are humbling. And they give us a deep perspective…on drugs.
Yes, this includes wow-the-stars-are-freaking-amazing-tonight drugs, but also the kinds of drugs that make us well again when we’re sick. The number of possible organic compounds with “drug-like” properties dwarfs the number of stars in the universe by over 30 orders of magnitude.
Next to this multiverse of possibility, the chemical configurations scientists have made into actual medicines are like the smattering of stars you’d glimpse downtown.
But for good reason.
Exploring all that potential drug-space is as humanly impossible as exploring all of physical space, and even if we could, most of what we’d find wouldn’t fit our purposes. Still, the idea that wonder drugs must surely lurk amid the multitudes is too tantalizing to ignore.
Which is why, Alex Zhavoronkov said at Singularity University’s Exponential Medicine in San Diego last week, we should use artificial intelligence to do more of the legwork and speed discovery. This, he said, could be one of the next big medical applications for AI.
Dogs, Diagnosis, and Drugs
Zhavoronkov is CEO of Insilico Medicine and CSO of the Biogerontology Research Foundation. Insilico is one of a number of AI startups aiming to accelerate drug discovery with AI.
In recent years, Zhavoronkov said, the now-famous machine learning technique, deep learning, has made progress on a number of fronts. Algorithms that can teach themselves to play games—like DeepMind’s AlphaGo Zero or Carnegie Mellon’s poker playing AI—are perhaps the most headline-grabbing of the bunch. But pattern recognition was the thing that kicked deep learning into overdrive early on, when machine learning algorithms went from struggling to tell dogs and cats apart to outperforming their peers and then their makers in quick succession.
[Watch this video for an AI update from Neil Jacobstein, chair of Artificial Intelligence and Robotics at Singularity University.]
In medicine, deep learning algorithms trained on databases of medical images can spot life-threatening disease with equal or greater accuracy than human professionals. There’s even speculation that AI, if we learn to trust it, could be invaluable in diagnosing disease. And, as Zhavoronkov noted, with more applications and a longer track record that trust is coming.
“Tesla is already putting cars on the street,” Zhavoronkov said. “Three-year, four-year-old technology is already carrying passengers from point A to point B, at 100 miles an hour, and one mistake and you’re dead. But people are trusting their lives to this technology.”
“So, why don’t we do it in pharma?”
Trial and Error and Try Again
AI wouldn’t drive the car in pharmaceutical research. It’d be an assistant that, when paired with a chemist or two, could fast-track discovery by screening more possibilities for better candidates.
There’s plenty of room to make things more efficient, according to Zhavoronkov.
Drug discovery is arduous and expensive. Chemists sift tens of thousands of candidate compounds for the most promising to synthesize. Of these, a handful will go on to further research, fewer will make it to human clinical trials, and a fraction of those will be approved.
The whole process can take many years and cost hundreds of millions of dollars.
This is a big data problem if ever there was one, and deep learning thrives on big data. Early applications have shown their worth unearthing subtle patterns in huge training databases. Although drug-makers already use software to sift compounds, such software requires explicit rules written by chemists. AI’s allure is its ability to learn and improve on its own.
“There are two strategies for AI-driven innovation in pharma to ensure you get better molecules and much faster approvals,” Zhavoronkov said. “One is looking for the needle in the haystack, and another one is creating a new needle.”
To find the needle in the haystack, algorithms are trained on large databases of molecules. Then they go looking for molecules with attractive properties. But creating a new needle? That’s a possibility enabled by the generative adversarial networks Zhavoronkov specializes in.
Such algorithms pit two neural networks against each other. One generates meaningful output while the other judges whether this output is true or false, Zhavoronkov said. Together, the networks generate new objects like text, images, or in this case, molecular structures.
“We started employing this particular technology to make deep neural networks imagine new molecules, to make it perfect right from the start. So, to come up with really perfect needles,” Zhavoronkov said. “[You] can essentially go to this [generative adversarial network] and ask it to create molecules that inhibit protein X at concentration Y, with the highest viability, specific characteristics, and minimal side effects.”
Zhavoronkov believes AI can find or fabricate more needles from the array of molecular possibilities, freeing human chemists to focus on synthesizing only the most promising. If it works, he hopes we can increase hits, minimize misses, and generally speed the process up.
Proof’s in the Pudding
Insilico isn’t alone on its drug-discovery quest, nor is it a brand new area of interest.
Last year, a Harvard group published a paper on an AI that similarly suggests drug candidates. The software trained on 250,000 drug-like molecules and used its experience to generate new molecules that blended existing drugs and made suggestions based on desired properties.
An MIT Technology Review article on the subject highlighted a few of the challenges such systems may still face. The results returned aren’t always meaningful or easy to synthesize in the lab, and the quality of these results, as always, is only as good as the data dined upon.
Stanford chemistry professor and Andreesen Horowitz partner, Vijay Pande, said that images, speech, and text—three of the areas deep learning’s made quick strides in—have better, cleaner data. Chemical data, on the other hand, is still being optimized for deep learning. Also, while there are public databases, much data still lives behind closed doors at private companies.
To overcome the challenges and prove their worth, Zhavoronkov said, his company is very focused on validating the tech. But this year, skepticism in the pharmaceutical industry seems to be easing into interest and investment.
AI drug discovery startup Exscientia inked a deal with Sanofi for $280 million and GlaxoSmithKline for $42 million. Insilico is also partnering with GlaxoSmithKline, and Numerate is working with Takeda Pharmaceutical. Even Google may jump in. According to an article in Nature outlining the field, the firm’s deep learning project, Google Brain, is growing its biosciences team, and industry watchers wouldn’t be surprised to see them target drug discovery.
With AI and the hardware running it advancing rapidly, the greatest potential may yet be ahead. Perhaps, one day, all 1060 molecules in drug-space will be at our disposal. “You should take all the data you have, build n new models, and search as much of that 1060 as possible” before every decision you make, Brandon Allgood, CTO at Numerate, told Nature.
Today’s projects need to live up to their promises, of course, but Zhavoronkov believes AI will have a big impact in the coming years, and now’s the time to integrate it. “If you are working for a pharma company, and you’re still thinking, ‘Okay, where is the proof?’ Once there is a proof, and once you can see it to believe it—it’s going to be too late,” he said.
Image Credit: Klavdiya Krinichnaya / Shutterstock.com Continue reading